Japanese pharmaceutical company specializing in eye-care drugs and treatments, sold globally.
Japanese pharmaceutical company specializing in eye-care drugs and treatments, sold globally.
Japan is the home market, where national insurance sets drug prices and cuts them in regular revisions, so growth leans on Asia, notably China, and Europe, and on new eye drugs. Sales are mostly prescription products reaching patients through eye doctors and hospitals.
In one line: A global ophthalmology-focused pharma, like a smaller Bausch + Lomb pharma arm.
Moat: narrow (IP / patents, brand). Focused therapeutic-area expertise and patents in ophthalmology, a niche most large pharma underserve.
Headquarters: Osaka, Japan · Founded: 1890 · Employees: 3,968
Size Santen Pharmaceutical (4536.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $4.14B, the 290th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,056 on 18 Nov 2026.
Performance Over six months the shares gained 10.5%, against +0.8% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 1.9% over the last twelve months (peer median +5.8%); the operating margin is 15.8% (peer median 19.2%).
Valuation It trades at 16.7× forward earnings against a peer median of 25.2× (5th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.8 points above its cost of capital (5.0% WACC).
Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥297B | ¥292B | ¥300B | ¥302B | ¥279B |
| Revenue growth | — | -3% | -1% | +8% | — |
| Gross profit | ¥167B | ¥155B | ¥163B | ¥164B | ¥157B |
| EBITDA | ¥64.9B | ¥63.6B | ¥74.2B | ¥70.1B | ¥49.3B |
| Net income | ¥38.9B | ¥37.4B | ¥36.2B | ¥26.6B | -¥15.0B |
| Free cash flow | ¥41.3B | ¥36.7B | ¥54.3B | ¥63.3B | ¥19.9B |
| Capital expenditure | ¥13.6B | ¥14.3B | ¥11.0B | ¥10.7B | ¥24.6B |
| Total debt | ¥32.2B | ¥34.8B | ¥34.2B | ¥35.2B | ¥36.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Santen Pharmaceutical 4536.T | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% |
| Alcon ALC.SW | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% |
| Bausch + Lomb BLCO.TO | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% |
| Otsuka Hldgs 4578.T | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% |
| Rohto Pharmaceutical 4527.T | $3.87B | +8% | +7% | 12% | 16.5× | -2.8% |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 17.5× | 1.6% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 18.1× | -0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4536.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.1% | +0.2% | 3rd highest of 21 |
| 6-month return | +10.5% | +0.8% | 8th highest of 20 |
| Distance from 52-week high | -8.8% | -26.4% | 5th highest of 21 |
| Revenue growth (TTM) | +1.9% | +5.8% | 8th lowest of 19 |
| Operating margin | 15.8% | 19.2% | 9th lowest of 18 |
| Forward P/E | 16.7× | 25.2× | 5th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -5.0% | 6.4% | 3rd least demanding of 16 |
| Growth delivered (Del g) | +3.2% | +7.5% | 6th lowest of 16 |
| Hurdle (Req g minus delivered) | -8.2 pp | -3.1 pp | 7th least demanding of 16 |
| ROIC minus cost of capital | +7.8 pp | +6.9 pp | 8th highest of 18 |
| EV / EBITDA | 9.4× | 22.8× | 2nd cheapest of 9 |
| Net debt / EBITDA | -0.8× | -0.1× | 3rd least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% | +3.2% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 40.4× | n/a | n/a |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% | +9.7% |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% | +7.5% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | n/a | 57.4% | +3.1% |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | China | $4.45B | -13% | +1% | 3% | 12.9× | -0.7% | +4.7% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% | +45.1% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Livzon Pharmaceutical 000513.SZ | China | $3.76B | +4% | -14% | 19% | 16.9× | -9.6% | +2.7% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 28.5× | 16.2% | -5.8% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 21.9× | 1.2% | +12.1% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | n/a | 34.7% | +159.5% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |